Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
NHLBI Catalyze grants fund platform technologies to accelerate the development of diagnostics and therapeutics for heart, lung, blood, and sleep disorders.
Funder: National Institutes of Health
Due Dates: June 18, 2025 (New/Renewal/Resubmission) | October 21, 2025 (New/Renewal/Resubmission) | June 18, 2026 (New/Renewal/Resubmission) | October 21, 2026 (New/Renewal/Resubmission) | June 17, 2027 (New/Renewal/Resubmission) | October 21, 2027 (New/Renewal/Resubmission)
Funding Amounts: Up to $350,000 direct costs per year, max 2 years; typical total award up to $700,000 direct costs.
Summary: Supports rigorous validation of transformative, multi-use platform technologies to accelerate diagnostics and therapeutics for heart, lung, blood, and sleep (HLBS) disorders; clinical trials are not allowed.
Key Information: Projects must focus on enabling technology/platform development (not single-use applications); preliminary feasibility data required; foreign organizations are not eligible to apply.
Description
This funding opportunity, offered by the National Heart, Lung, and Blood Institute (NHLBI) under the NIH Catalyze program, supports the further development and rigorous validation of enabling technologies and transformative platforms that can catalyze next-generation predictive, diagnostic, and therapeutic products for heart, lung, blood, and sleep (HLBS) disorders. The program is designed for projects where major feasibility gaps have already been overcome, as demonstrated by preliminary data, but where further development and validation are needed to encourage downstream adoption and utilization.
The focus is on technologies and platforms with the potential to significantly accelerate or transform early detection, screening, model development, clinical diagnosis, treatment, control, prevention, or epidemiology of HLBS-related diseases. Projects must be at a mid-stage technology readiness level (TRL 3–4) and should not be limited to a single disease or application.
Clinical trials are not permitted under this opportunity.
